• Je něco špatně v tomto záznamu ?

Dual inhibition of nitric oxide and prostaglandin E2 production by polysubstituted 2-aminopyrimidines

Z. Zídek, M. Kverka, A. Dusilová, E. Kmoníčková, P. Jansa,

. 2016 ; 57 (-) : 48-56. [pub] 20160429

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18011240

The present in vitro experiments demonstrate inhibitory effects of polysubstituted 2-aminopyrimidines on high output production of nitric oxide (NO) and prostaglandin E2 (PGE2) stimulated by interferon-γ and lipopolysaccharide (LPS) in peritoneal macrophages of mouse and rat origin. PGE2 production was inhibited also in LPS-activated human peripheral blood mononuclear cells. A tight dependence of the suppressive activities on chemical structure of pyrimidines was observed. Derivatives containing hydroxyl groups at the C-4 and C-6 positions of pyrimidine ring were devoid of any influence on NO and PGE2. Remarkable inhibitory potential was acquired by the replacement of hydroxyl groups with chlorine, the 4,6-dichloro derivatives being more effective than the monochloro analogues. The effects were further intensified by modification of the amino group at the C-2 position, changing it to the (N,N-dimethylamino)methyleneamino or the formamido ones. There was no substantial difference in the expression of NO-inhibitory effects among derivatives containing distinct types of substituents at the C-5 position (hydrogen, methyl, ethyl, propyl, butyl, phenyl, and benzyl). In contrast to NO, larger substituents then methyl were required to inhibit PGE2 production. Overall, no significant correlation between the extent of NO and PGE2 suppression was observed. The IC50s of derivatives with the strongest effects on both NO and PGE2 were within the range of 2-10 μM. Their NO-inhibitory potential of pyrimidines was stronger than that of non-steroidal anti-inflammatory drugs (NSAIDs) aspirin and indomethacin. The PGE2-inhibitory effectiveness of pyrimidines was about the same as that of aspirin, but weaker as compared to indomethacin. The NO- and PGE2-inhibitory activity of tested pyrimidines has been found associated with decreased expression of iNOS mRNA and COX-2 mRNA, respectively, and with post-translation interactions. Selected NO-/PGE2-inhibitory derivatives decreased severity of intestinal inflammation in murine model of ulcerative colitis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011240
003      
CZ-PrNML
005      
20180416095533.0
007      
ta
008      
180404s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.niox.2016.04.008 $2 doi
035    __
$a (PubMed)27133739
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zídek, Zdeněk $u Institute of Experimental Medicine, The Czech Academy of Sciences, Vídeňská 1083, 14220, Prague 4, Czech Republic. Electronic address: zidekz@biomed.cas.cz.
245    10
$a Dual inhibition of nitric oxide and prostaglandin E2 production by polysubstituted 2-aminopyrimidines / $c Z. Zídek, M. Kverka, A. Dusilová, E. Kmoníčková, P. Jansa,
520    9_
$a The present in vitro experiments demonstrate inhibitory effects of polysubstituted 2-aminopyrimidines on high output production of nitric oxide (NO) and prostaglandin E2 (PGE2) stimulated by interferon-γ and lipopolysaccharide (LPS) in peritoneal macrophages of mouse and rat origin. PGE2 production was inhibited also in LPS-activated human peripheral blood mononuclear cells. A tight dependence of the suppressive activities on chemical structure of pyrimidines was observed. Derivatives containing hydroxyl groups at the C-4 and C-6 positions of pyrimidine ring were devoid of any influence on NO and PGE2. Remarkable inhibitory potential was acquired by the replacement of hydroxyl groups with chlorine, the 4,6-dichloro derivatives being more effective than the monochloro analogues. The effects were further intensified by modification of the amino group at the C-2 position, changing it to the (N,N-dimethylamino)methyleneamino or the formamido ones. There was no substantial difference in the expression of NO-inhibitory effects among derivatives containing distinct types of substituents at the C-5 position (hydrogen, methyl, ethyl, propyl, butyl, phenyl, and benzyl). In contrast to NO, larger substituents then methyl were required to inhibit PGE2 production. Overall, no significant correlation between the extent of NO and PGE2 suppression was observed. The IC50s of derivatives with the strongest effects on both NO and PGE2 were within the range of 2-10 μM. Their NO-inhibitory potential of pyrimidines was stronger than that of non-steroidal anti-inflammatory drugs (NSAIDs) aspirin and indomethacin. The PGE2-inhibitory effectiveness of pyrimidines was about the same as that of aspirin, but weaker as compared to indomethacin. The NO- and PGE2-inhibitory activity of tested pyrimidines has been found associated with decreased expression of iNOS mRNA and COX-2 mRNA, respectively, and with post-translation interactions. Selected NO-/PGE2-inhibitory derivatives decreased severity of intestinal inflammation in murine model of ulcerative colitis.
650    _2
$a zvířata $7 D000818
650    _2
$a antiflogistika nesteroidní $x aplikace a dávkování $x farmakologie $7 D000894
650    _2
$a Aspirin $x farmakologie $7 D001241
650    _2
$a ulcerózní kolitida $x farmakoterapie $x patofyziologie $7 D003093
650    _2
$a kolon $x účinky léků $x metabolismus $7 D003106
650    _2
$a cyklooxygenasa 2 $x genetika $x metabolismus $7 D051546
650    _2
$a dinoproston $x antagonisté a inhibitory $x biosyntéza $7 D015232
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a indomethacin $x farmakologie $7 D007213
650    _2
$a interferon gama $x farmakologie $7 D007371
650    _2
$a lipopolysacharidy $x farmakologie $7 D008070
650    _2
$a peritoneální makrofágy $x účinky léků $x metabolismus $7 D017737
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a mitogenem aktivované proteinkinasy $x metabolismus $7 D020928
650    _2
$a oxid dusnatý $x antagonisté a inhibitory $x biosyntéza $7 D009569
650    _2
$a synthasa oxidu dusnatého, typ II $x genetika $x metabolismus $7 D052247
650    _2
$a pyrimidiny $x aplikace a dávkování $x farmakologie $7 D011743
650    _2
$a messenger RNA $x metabolismus $7 D012333
650    _2
$a potkani inbrední LEW $7 D011917
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kverka, Miloslav $u Institute of Experimental Medicine, The Czech Academy of Sciences, Vídeňská 1083, 14220, Prague 4, Czech Republic; Institute of Microbiology, The Czech Academy of Sciences, Vídeňská 1083, 14220, Prague 4, Czech Republic.
700    1_
$a Dusilová, Adéla $u Institute of Experimental Medicine, The Czech Academy of Sciences, Vídeňská 1083, 14220, Prague 4, Czech Republic; Institute of Microbiology, The Czech Academy of Sciences, Vídeňská 1083, 14220, Prague 4, Czech Republic.
700    1_
$a Kmoníčková, Eva $u Institute of Experimental Medicine, The Czech Academy of Sciences, Vídeňská 1083, 14220, Prague 4, Czech Republic.
700    1_
$a Jansa, Petr $u Institute of Organic Chemistry and Biochemistry, The Czech Academy of Sciences, Flemingovo nám. 2, 16610, Prague 6, Czech Republic.
773    0_
$w MED00004882 $t Nitric oxide $x 1089-8611 $g Roč. 57, č. - (2016), s. 48-56
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27133739 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180416095630 $b ABA008
999    __
$a ok $b bmc $g 1288725 $s 1008052
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 57 $c - $d 48-56 $e 20160429 $i 1089-8611 $m Nitric oxide $n Nitric oxide $x MED00004882
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...